Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
MENLO PARK, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its Fourth Quarter and Year End 2015 Financial Results on Tuesday, February 2, 2016, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: February 2, 2016
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Pacific Biosciences' technology provides the industry's highest consensus accuracy over the longest read lengths in combination with the ability to detect real-time kinetic information. PacBio sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Contact: Pacific Biosciences Trevin Rard 650.521.8450 [email protected]
